9,855 results match your criteria Gastrointestinal Stromal Tumors

Progressive cerebellar atrophy in a patient with complex II and III deficiency and a novel deleterious variant in SDHA: A Counseling Conundrum.

Mol Genet Genomic Med 2021 May 7:e1692. Epub 2021 May 7.

Metabolism, Infection and Immunity Section, National Human Genome Research Institute, NIH, Bethesda, MD, USA.

Background: Complex II is an essential component of the electron transport chain, linking it with the tricarboxylic acid cycle. Its four subunits are encoded in the nuclear genome, and deleterious variants in these genes, including SDHA (OMIM 600857), are associated with a wide range of symptoms including neurological disease, cardiomyopathy, and neoplasia (paraganglioma-pheochromocytomas (PGL/PCC), and gastrointestinal stromal tumors). Deleterious variants of SDHA are most frequently associated with Leigh and Leigh-like syndromes. Read More

View Article and Full-Text PDF

Massive Gastrointestinal Haemorrhage Unusual Presentation of Gastrointestinal Stromal Tumors of the Jejunum: Case Report and Literature Review.

Cureus 2021 Apr 2;13(4):e14266. Epub 2021 Apr 2.

Department of Intensive Care Medicine, National Guard Hospital, Al Madinah, SAU.

Although gastrointestinal stromal tumors (GISTs) are rare tumors, they are the most common tumors of mesenchymal origin of the gastrointestinal tract. GISTs present with nonspecific clinical manifestation and they are discovered incidentally during endoscopic or radiological investigations. Massive life-threatening bleeding that requires urgent surgery is rare. Read More

View Article and Full-Text PDF

Ripretinib for the treatment of advanced gastrointestinal stromal tumor.

John R Zalcberg

Therap Adv Gastroenterol 2021 15;14:17562848211008177. Epub 2021 Apr 15.

Department of Medical Oncology, Alfred Health and the School of Public Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.

Gastrointestinal stromal tumors (GISTs) are rare tumors of the gastrointestinal (GI) tract yet represent the most common GI sarcomas. Most GISTs are driven by activating mutations of the and/or genes. Prior to the development of tyrosine kinase inhibitors (TKIs), GISTs were associated with a poor prognosis because conventional cytotoxic chemotherapy was relatively ineffective. Read More

View Article and Full-Text PDF

Ripretinib and MEK inhibitors synergize to induce apoptosis in preclinical models of GIST and Systemic Mastocytosis.

Mol Cancer Ther 2021 May 4. Epub 2021 May 4.

Biology, Deciphera Pharmaceuticals, LLC

The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first, second, and third-line targeted therapies, respectively, for metastatic or unresectable KIT-driven GIST. Treatment of GIST patients with KIT kinase inhibitors generally leads to a partial response or stable disease but most patients eventually progress by developing secondary resistance mutations in KIT. Read More

View Article and Full-Text PDF

Reversing Imatinib's Immunosuppressive Effects by Modulating Type I IFN Signaling.

Cancer Immunol Res 2021 May;9(5):489

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.

Signal pathway inhibition is a well-validated approach for treating cancers driven by activated kinases such as KIT. However, kinase inhibitors may make tumor cells less responsive to tumor immune surveillance and less sensitive to immunotherapies. In this issue, Liu and colleagues report that, in a mouse model, inhibition of oncogenic KIT in gastrointestinal stromal tumors reduces type I interferon (IFN) production and signaling, and the effectiveness of the immune system in controlling tumor growth. Read More

View Article and Full-Text PDF

TGF-β signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer.

Gastroenterology 2021 Apr 30. Epub 2021 Apr 30.

Center for Translational Medicine, Department of Surgery, The George Washington University, Washington, DC 20037, USA. Electronic address:

Genetic alterations affecting transforming growth factor β (TGF-β) signaling are exceptionally common in diseases and cancers of the gastrointestinal (GI) system. As a regulator of tissue renewal, TGF-β signaling and the downstream SMAD-dependent transcriptional events play complex roles in the transition from a noncancerous disease state to cancer in the GI tract, liver, and pancreas. Furthermore, this pathway also regulates the stromal cells and the immune system, which may contribute to evasion of the tumors from immune-mediated elimination. Read More

View Article and Full-Text PDF

Characteristics of Gastrointestinal Stromal Tumors incidentally discovered during abdominal surgery.

Am J Surg 2021 Apr 22. Epub 2021 Apr 22.

Helen F Graham Cancer Center and Research Institute at Christiana Care Department of General and Surgical Oncology, Newark, DE, USA.

Background: Gastrointestinal Stromal Tumors (GISTs) are rare sarcomas with 5000 new cases arising in the United States each year. Despite their low incidence, general surgeons should be familiar with GISTs since a quarter of these neoplasms are encountered incidentally.

Methods: A retrospective medical records review was conducted to create a database of all GISTs resected from January 2005 to May 2019. Read More

View Article and Full-Text PDF

A nationwide survey on esophageal gastrointestinal stromal tumors at accredited institutions by the Japan Esophageal Society.

Esophagus 2021 Apr 29. Epub 2021 Apr 29.

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Background: As esophageal gastrointestinal stromal tumors (GISTs) are very rare, their clinicopathological features remain obscure. We conducted a nationwide survey to clarify the characteristics of these tumors and to establish a consensus on their diagnosis and treatment.

Methods: The clinicopathological information of patients with esophageal GISTs who underwent treatment between January 2010 and June 2016 at the accredited institutions by the Japan Esophageal Society was collected via a questionnaire method and analyzed statistically. Read More

View Article and Full-Text PDF

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?

Cancers (Basel) 2021 Apr 27;13(9). Epub 2021 Apr 27.

Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy.

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Read More

View Article and Full-Text PDF

Feasibility of Non-Exposure Simple Suturing Endoscopic Full-Thickness Resection in Comparison with Laparoscopic Endoscopic Cooperative Surgery for Gastric Subepithelial Tumors: Results of Two Independent Prospective Trials.

Cancers (Basel) 2021 Apr 13;13(8). Epub 2021 Apr 13.

Center for Gastric Cancer, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Korea.

Recently, nonexposure simple suturing endoscopic full-thickness resection (NESS-EFTR) method was developed to avoid tumor exposure to the peritoneal cavity. The aim of this study is to compare the short-term outcomes of the NESS-EFTR method with those of laparoscopic and endoscopic cooperative surgery (LECS) for gastric subepithelial tumors (SETs). A prospective single-center trial of LECS for gastric SETs was performed from March 2012 to October 2013 with a separate prospective trial of NESS-EFTR performed from August 2015 to June 2017, enrolling 15 patients each. Read More

View Article and Full-Text PDF

Preoperative Diagnosis Failure for a Rare Gastric Collision Tumor: A Case Report.

Diagnostics (Basel) 2021 Apr 1;11(4). Epub 2021 Apr 1.

Department of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.

Gastrointestinal stromal tumors (GISTs) are common mesenchymal tumors of the gastrointestinal tract (GIT), usually occur as a solitary neoplasm. Inflammatory florid polyp (IFP) is a solitary rare benign lesion of the gastrointestinal tract, mainly occur in the gastric antrum, whose atypical presentation can mimic GISTs or other malignant tumors, therefore the synchronous occurrence of GISTs and IFP is extremely rare. We had a case of a 58-year-old man that was presented with recurrent epigastric pain and recurrent melena. Read More

View Article and Full-Text PDF

Intragastric Single-Port Surgery: An Innovative and Multipurpose Technique for the Therapy of Upper Digestive Tract Lesions.

Surg Innov 2021 Apr 29:15533506211015386. Epub 2021 Apr 29.

Center for Bariatric and Metabolic Surgery, 14959Klinikum Ernst von Bergmann, Academic Hospital of the Charité-Universitätsmedizin Humboldt University Berlin, Potsdam, Germany.

: Endoscopic treatment can represent a technical challenge for several special situations, such as resecting gastric tumors with larger size or in unfavorable sites and performing endoscopic retrograde cholangiopancreatography (ERCP) after Roux-en-Y gastric bypass (RYGB). This study aims to describe an innovative and multipurpose technique, intragastric single-port surgery (IGS), which can be applied for abovementioned special situations and for assessing its safety, feasibility, and efficacy. : IGS technique was performed through a 2-3 cm skin incision, where the stomach wall is exteriorized and fixed to the skin. Read More

View Article and Full-Text PDF

Gastric gastrointestinal stromal tumor (GIST) with co-occurrence of pancreatic neuroendocrine tumor.

Radiol Case Rep 2021 Jun 10;16(6):1391-1394. Epub 2021 Apr 10.

EVMS Radiology Department, Eastern Virginia Medical School, 700 W Olney Rd, Norfolk, VA 23507, USA.

Mesenchymal tumors make up only about 1% of primary GI tumors, with Gastrointestinal Stromal Tumors (GIST) being the most common nonepithelial GI neoplasms. They are derived from the Interstitial cells of Cajal (ICC), and occur predominantly in older individuals, with a mean age of diagnosis of 64 years. Here we discuss the case of a 39-year-old female with atypical thoracic back pain wrapping around to the front and migrating diffuse abdomen pain that sometimes radiates into the chest. Read More

View Article and Full-Text PDF

Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice.

Gastric Cancer 2021 Apr 28. Epub 2021 Apr 28.

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Background: Molecular analysis of KIT and PDGFRA is critical for tyrosine kinase inhibitor treatment selection of gastrointestinal stromal tumors (GISTs) and hence recommended by international guidelines. We performed a nationwide study into the application of predictive mutation testing in GIST patients and its impact on targeted treatment decisions in clinical practice.

Methods: Real-world clinical and pathology information was obtained from GIST patients with initial diagnosis in 2017-2018 through database linkage between the Netherlands Cancer Registry and the nationwide Dutch Pathology Registry. Read More

View Article and Full-Text PDF

Gastrointestinal Stromal Tumor as a Rare Cause of Abdominal Mass: A Case Report and Literature Review.

Cureus 2021 Mar 23;13(3):e14070. Epub 2021 Mar 23.

Internal Medicine, BronxCare Health System, New York, USA.

Gastrointestinal stromal tumors (GISTs) are soft tissue sarcomas that can arise from any part of the digestive system. GISTs represent 1% of gastric neoplasms. We report a rare case of a GIST tumor in a 59-year-old woman who presented with abdominal pain and weight loss. Read More

View Article and Full-Text PDF

Uncommon indications for associating liver partition and portal vein ligation for staged hepatectomy: a systematic review.

Hepatobiliary Surg Nutr 2021 Apr;10(2):210-225

Hepatobiliary Surgery and Organ Transplantation Unit, Department of General Surgery and Organ Transplantation, Sapienza University of Rome, Rome, Italy.

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) represents an innovative surgical technique used for the treatment of large hepatic lesions at high risk for post-resection liver failure due to a small future liver remnant. The most significant amount of literature concerns the use of ALPPS for the treatment of hepatocellular carcinoma (HCC), cholangiocarcinoma (CCC), and colorectal liver metastases (CRLM). On the opposite, few is known about the role of ALPPS for the treatment of uncommon liver pathologies. Read More

View Article and Full-Text PDF

Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors.

Eur Radiol 2021 Apr 21. Epub 2021 Apr 21.

Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, 90127, Palermo, Italy.

Objectives: To investigate the correlation between CT imaging features and risk stratification of gastrointestinal stromal tumors (GISTs), prediction of mutation status, and prognosis.

Methods: This retrospective dual-institution study included patients with pathologically proven GISTs meeting the following criteria: (i) preoperative contrast-enhanced CT performed between 2008 and 2019; (ii) no treatments before imaging; (iii) available pathological analysis. Tumor risk stratification was determined according to the National Institutes of Health (NIH) 2008 criteria. Read More

View Article and Full-Text PDF

The many faces of solitary fibrous tumor; diversity of histological features, differential diagnosis and role of molecular studies and surrogate markers in avoiding misdiagnosis and predicting the behavior.

Diagn Pathol 2021 Apr 20;16(1):32. Epub 2021 Apr 20.

Emeritus Professor, Kyung Hee University, School of Medicine Vice President of Asia, International Academy of Pathology, U2Labs, Jangwon Medical Foundation 68 Geoma-ro, Songpa-gu, Seoul, 05755, South Korea.

Background: Solitary Fibrous Tumor (SFT) is a distinct soft tissue neoplasm associated with NAB2-STAT6 gene fusion. It can involve a number of anatomic sites and exhibits a wide spectrum of histological features.

Main Body: Apart from diversity in morphological features seen even in conventional SFT, two histologic variants (fat-forming and giant cell-rich) are also recognized. Read More

View Article and Full-Text PDF

Mutations in ALK and TSC1 in a gastrointestinal stromal tumor: a case report.

BMC Surg 2021 Apr 20;21(1):202. Epub 2021 Apr 20.

Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, Shenzhen, 518036, Guangdong, People's Republic of China.

Background: Gastrointestinal stromal tumors rarely occur in children, but when they do, their biological behavior and histopathological patterns differ from those of adults.

Case Presentation: A 13-year-old boy with a gastrointestinal stromal tumor was characterized by a rare genetic mutation. The patient complained of "fatigue with intermittent abdominal pain for 1 month". Read More

View Article and Full-Text PDF

Gastrointestinal stromal tumor: a review of current and emerging therapies.

Cancer Metastasis Rev 2021 Apr 19. Epub 2021 Apr 19.

Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, MI, USA.

Gastrointestinal stromal tumors (GIST) are rare neoplasms arising from the interstitial cell of Cajal in the gastrointestinal tract. Two thirds of GIST in adult patients have c-Kit mutation and smaller fractions have platelet derived growth factor receptor alpha (PDGFRA) mutation. Surgery is the only curative treatment for localized disease. Read More

View Article and Full-Text PDF

Gastric and Small Intestine Gist: Results of 156 Cases in 20 Years.

J Gastrointest Cancer 2021 Apr 19. Epub 2021 Apr 19.

Esofagogastric Unit, Bellvitge University Hospital, de La Feixa Llarga, s/n L´Hospitalet de Llobregat, Barcelona, Spain.

Purpose: Gastric and small intestine are the most common gastrointestinal stromal tumors (GISTs). There are few studies of patients who underwent surgical treatment with disparate findings. We aimed to evaluate the differences between groups and the risk factors for recurrence and mortality. Read More

View Article and Full-Text PDF

Surgical resection of gastric gastrointestinal stromal tumors (GIST) in octogenarians.

Am J Surg 2021 Apr 15. Epub 2021 Apr 15.

Division of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, 3400 Spruce Street, 4 Silverstein, Philadelphia, PA, 19146, USA.

Background: Localized gastrointestinal stromal tumors (GISTs) are rare tumors typically managed with surgery, but outcomes among octogenarians remain less studied.

Methods: Octogenarian patients with stage I-III gastric GISTs were identified from the National Cancer Database and classified by resection status. Cox regression and Kaplan-Meier survival analyses analyzed 5-year overall survival (OS). Read More

View Article and Full-Text PDF

PDGFRA Immunohistochemistry Predicts PDGFRA Mutations in Gastrointestinal Stromal Tumors.

Am J Surg Pathol 2021 Apr 12. Epub 2021 Apr 12.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA Department of Pathology, Stanford University School of Medicine, Stanford, CA.

Platelet-derived growth factor receptor A (PDGFRA) is a receptor tyrosine kinase that is activated by mutations in 10% of gastrointestinal stromal tumors (GISTs) and 55% to 70% of inflammatory fibroid polyps. PDGFRA-mutant GISTs are usually epithelioid and occur predominantly in the stomach. Succinate dehydrogenase-deficient GISTs also arise in the stomach and are usually epithelioid, as are some KIT-mutant GISTs. Read More

View Article and Full-Text PDF

Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review.

J Int Med Res 2021 Apr;49(4):3000605211007050

Department of Colorectal and Anal Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.

Radical resection with or without adjuvant chemotherapy is a common option for stage II and III colorectal cancer. Few reports exist regarding gastric tumorigenesis, including gastric cancer, gastric intraepithelial neoplasia, and gastric stromal tumor, in patients who received this protocol as the standard treatment for colorectal cancer. We present two cases of gastric tumorigenesis in patients with colorectal cancer following radical resection combined with adjuvant chemotherapy. Read More

View Article and Full-Text PDF

Preoperative imaging of gastric GISTs underestimates pathologic tumor size: A retrospective, single institution analysis.

J Surg Oncol 2021 Apr 15. Epub 2021 Apr 15.

Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada.

Background: How well imaging size agrees with pathologic size of gastric gastrointestinal stromal tumors (GISTs) is unknown. GIST risk stratification is based on pathologic size, location, and mitotic rate. To inform decision making, the size discrepancy between imaging and pathology for gastric GISTs was investigated. Read More

View Article and Full-Text PDF

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.

Eur J Drug Metab Pharmacokinet 2021 May 14;46(3):343-352. Epub 2021 Apr 14.

Pfizer Oncology, Global Product Development, La Jolla, CA, USA.

Background And Objective: Population pharmacokinetic analysis explored the pharmacokinetics of sunitinib and its primary active metabolite, SU012662, in children and evaluated the sunitinib dose(s) that produce comparable plasma exposures to adults receiving the approved daily dose.

Methods: Data were from 65 children with gastrointestinal stromal tumors (GIST) or solid tumors. Pharmacokinetic models of sunitinib and SU012662 were developed using a systematic multi-step approach employing nonlinear mixed-effects modeling. Read More

View Article and Full-Text PDF

Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes.

Oncol Lett 2021 May 28;21(5):417. Epub 2021 Mar 28.

Department of Cancer Prevention, Medical University of Warsaw, 02-091 Warsaw, Poland.

A gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the human gastrointestinal tract, with an estimated incidence of 10-15 per 1 million per year. While preparing holistic care for patients with GIST diagnosis, scientists might face several difficulties - insufficient risk stratification, acquired or secondary resistance to imatinib, or the need for an exceptional therapy method associated with wild-type tumors. This review summarizes recent advances associated with GIST biology that might enhance diagnostic and therapeutic strategies. Read More

View Article and Full-Text PDF

Limited Resection Versus Pancreaticoduodenectomy for Duodenal Gastrointestinal Stromal Tumors? Enucleation Interferes in the Debate: A European Multicenter Retrospective Cohort Study.

Ann Surg Oncol 2021 Apr 10. Epub 2021 Apr 10.

Department of Digestive and Oncological Surgery, University Lille, Claude Huriez University Hospital, CHU de Lille, Lille, France.

Background: The optimal surgical procedure for duodenal gastrointestinal stromal tumors (D-GISTs) remains poorly defined. Pancreaticoduodenectomy (PD) allows for a wide resection but is associated with a high morbidity rate.

Objectives: The aim of this study was to compare the short- and long-term outcomes of PD versus limited resection (LR) for D-GISTs and to evaluate the role of tumor enucleation (EN). Read More

View Article and Full-Text PDF

Ripretinib (Qinlock) for GIST.


Med Lett Drugs Ther 2021 04 5;63(1621):e56-e57. Epub 2021 Apr 5.

View Article and Full-Text PDF

An Artificial Intelligence System for Distinguishing Between Gastrointestinal Stromal Tumors and Leiomyomas Using Endoscopic Ultrasonography (with video).

Endoscopy 2021 Apr 7. Epub 2021 Apr 7.

The Affiliated Hospital of Qingdao University, Department of Gastroenterology, Qingdao, China.

Background Gastrointestinal stromal tumors (GISTs) and gastrointestinal leiomyomas (GILs) are the most common subepithelial lesions (SELs). All GISTs have malignant potential; however, GILs are considered benign. Current imaging cannot effectively distinguish GISTs from GILs. Read More

View Article and Full-Text PDF